Cited by 2Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Synaptic PET imaging using [11C]UCB‐J in frontotemporal dementia

Open access
Clarke, Mica TM, Mansur, Ayla, Rizzo, Gaia, Passchier, Jan, Lewis, Yvonne, Evans, Karleyton C, Chen, Laigao, Schwarz, Adam J. +6 more·2021·Alzheimer's & Dementia

Abstract

Background: A number of pathophysiological mechanisms are associated with neurodegeneration, including synaptic dysfunction and/or loss. Novel radiotracers which enable the quantification of synaptic proteins in vivo have not previously been explored in frontotemporal dementia (FTD). We used [11 C]UCB‐J PET to measure the density of synaptic vesicle protein 2A (SV2A) in FTD. Method: Six participants with behavioural variant FTD (mean age 61.8, SD 5.4) and 17 cognitively normal participants (63.7, 12.5) underwent 90‐minute dynamic acquisition PET scans following injection of [11 C]UCB‐J, with metabolite corrected arterial input function. Thirteen regions of interest (ROIs) were defined on individual MR images using the CIC anatomical atlas. Regional density was evaluated using the regional V T normalised to the V T in the centrum semiovale (DVR‐1). Groups were compared using Mann‐Whitney tests with Bonferroni correction for multiple comparisons. W‐scores were computed from the 17 controls, with age and gender as covariates, to compare the magnitude of group differences in regional volumes versus [11 C]UCB‐J distribution. Volumes were expressed as a percentage of total intracranial volume. A w‐score of <‐1.65 was considered abnormal. Result: We found significant reductions in regional density of SV2A in FTD compared to controls in multiple cortical and subcortical regions: frontal, temporal, parietal, insula, anterior cingulate and posterior cingulate cortices (all 0.001), as well as the hippocampus, amygdala, thalamus and cerebellum (all 0.001). The w‐score analysis revealed significant reductions in SV2A density in FTD in all 13 ROIs, with the greatest reduction in the anterior cingulate (‐4.2), and in volume in 8 ROIs, with the greatest reduction in the temporal lobe (‐6.4). The magnitude of SV2A density loss was greater than the magnitude of volume loss in most ROIs (9/13), and there was more variability in the reduction in volume than there was in SV2A density (SD range [11 C]UCB‐J 0.7‐2.1, volume 1.4‐3.9). Conclusion: Significant reductions in [11 C]UCB‐J distribution indicate reduced synaptic density in disease‐relevant regions in FTD, which surpass reductions in volume. This suggests that [11 C]UCB‐J PET imaging could be a sensitive biomarker of synaptic dysfunction in FTD, with future studies focused on its relationship with symptoms and whether it becomes abnormal before symptom onset.

Integrity signals

Registry

Crossref · 10.1002/alz.054210

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Severe synaptic loss has been observed using 11C-UCBJ PET in series of cases with DLB, FTD, PD, PDD, PSP, CBD, and C9Orf72 mutation carriers.

    “while severe synaptic loss has been observed using 11C -UCBJ PET in series of cases with DLB, FTD, PD, PDD, PSP, CBD and C9Orf72 mutation carriers [205–209].”

Cited by

Sorted by citations

Authors
Clarke, M. T., Mansur, A., Rizzo, G., Passchier, J., Lewis, Y., Evans, K. C., Chen, L., Schwarz, A. J., Takano, A., Gunn, R. N., Cash, D. M., Rabiner, E. A., Rohrer, J. D., & MINDMAPS Consortium
Affiliations
  • UCL Queen Square Institute of Neurology (GB)
  • Invicro (United Kingdom) (GB)
  • Biogen (United States) (US)
  • Pfizer (United States) (US)
  • MINDMAPS Consortium London United Kingdom
  • Takeda (Japan) (JP)
  • King's College London (GB)
Corresponding author
Clarke, Mica TM
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2021-12
Volume
17
Issue
S4
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4210475433
Cited by
2
References
0
Citations by year
2023: 1 · 2020: 1
FWCI
0.18
Type
journal article
Language
en
Open access
Locations
Alzheimer s & Dementia (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
SV2A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review